Analysts Issue These New Stock Ratings and Price Targets Today

Wall St. Watchdog reveals information about companies for which stock analysts initiated coverage on November 11th.

  • Gamestop (NYSE:GME): Monness Crespi & Hardt initiated coverage of this company with a rating of Sell and a price target of $18.5. About the company: GameStop Corporation operates specialty electronic game and PC entertainment software stores throughout the United States, Australia, Canada and Europe. The Company stores sell new and used video game hardware, video game software and accessories, as well as PC entertainment software, and related accessories and other merchandise. Get the most recent company news and stock data here >>
  • Plains Exploration (NYSE:PXP): KeyBanc Capital Mkts initiated coverage of this company with a rating of Buy and a price target of $45. About the company: Plains Exploration & Production Company is an independent oil and gas company with onshore and offshore operations in California, West Texas, East Texas and the Gulf Coast region. The Company is primarily involved in the upstream activities of acquiring, exploiting, developing, and producing oil and gas. Get the most recent company news and stock data here >>
  • Entegris (NASDAQ:ENTG): Stifel Nicolaus initiated coverage of this company with a rating of Buy and a price target of $12. About the company: Entegris Inc. provides materials management products and services to the microelectronics industry on a worldwide basis. The Company provides products such as wafer shippers, wafer transport and process carriers, pods, and work-in-process boxes. Entegris also provides chemical delivery products such as valves, fittings, tubing, pipe, and containers. Get the most recent company news and stock data here >>
  • Ardent Mines (ADNT): Rodman & Renshaw initiated coverage of this company with a rating of Mkt Perform. Get the most recent company news and stock data here >>
  • Seattle Genetics (NASDAQ:SGEN): Needham initiated coverage of this company with a rating of Buy and a price target of $20. About the company: Seattle Genetics, Inc. discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. The Company’s technologies increase the potency and efficacy of monoclonal antibodies with specificity for cancer. Get the most recent company news and stock data here >>
  • Micromet (NASDAQ:MITI): Needham initiated coverage of this company with a rating of Buy and a price target of $10. About the company: Micromet, Inc. is a biotechnology company. The Company develops novel antibody-based drugs for the treatment of cancer, inflammation and autoimmune diseases. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>